Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and Angiogenesis, Pathologic

olmesartan has been researched along with Angiogenesis, Pathologic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Ge, X; Wang, SN; Wu, Y; Zhang, CQ1
Bhosale, V; Hanif, K; Jagavelu, K; Jain, M; Pal, N; Singh, H; Tripathi, D1
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA1
Bando, YK; Cheng, XW; Hu, L; Inoue, A; Kuzuya, M; Murohara, T; Okumura, K; Sasaki, T; Shi, GP; Song, H1
Fukami, K; Imaizumi, T; Inoue, H; Matsui, T; Nakamura, K; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S1

Other Studies

5 other study(ies) available for olmesartan and Angiogenesis, Pathologic

ArticleYear
Olmesartan Improves Hepatic Sinusoidal Remodeling in Mice with Carbon Tetrachloride-Induced Liver Fibrosis.
    BioMed research international, 2022, Volume: 2022

    Topics: Angiotensin II; Animals; Carbon Tetrachloride; Collagen; Imidazoles; Interleukin-10; Liver Cirrhosis; Mice; Neovascularization, Pathologic; Tetrazoles; Vascular Endothelial Growth Factor A

2022
Antihypertensive Drugs Aliskiren, Nebivolol, and Olmesartan Reduce Hypertension by Reducing Endothelial Microparticles and Regulating Angiogenesis.
    Journal of cardiovascular pharmacology, 2017, Volume: 70, Issue:3

    Topics: Amides; Animals; Antihypertensive Agents; Cell-Derived Microparticles; Drug Therapy, Combination; Fumarates; Humans; Hypertension; Imidazoles; Male; Nebivolol; Neovascularization, Pathologic; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles

2017
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014
Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:5

    Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Dietary Fats; Enzyme-Linked Immunosorbent Assay; Imidazoles; Male; Matrix Metalloproteinase 2; Mice; Mice, Knockout; Neovascularization, Pathologic; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tetrazoles; Toll-Like Receptor 2; Toll-Like Receptor 4; Tunica Intima

2011
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
    Microvascular research, 2008, Volume: 75, Issue:1

    Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Cells, Cultured; Diabetic Retinopathy; DNA Replication; Down-Regulation; Endothelial Cells; Glycation End Products, Advanced; Humans; Imidazoles; Neovascularization, Pathologic; NF-kappa B; Promoter Regions, Genetic; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Research Design; RNA, Messenger; Tetrazoles; Transfection; Vascular Endothelial Growth Factor A

2008